

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 884 052 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
16.12.1998 Bulletin 1998/51

(21) Application number: 96938460.1

(22) Date of filing: 14.11.1996

(51) Int. Cl.⁶: **A61K 38/18**, A61K 47/32,
A61F 2/28, A61B 17/56,
A61M 37/00(86) International application number:
PCT/JP96/03333(87) International publication number:
WO 97/18829 (29.05.1997 Gazette 1997/23)(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE

(30) Priority: 17.11.1995 JP 322402/95

(71) Applicant:
Hoechst Marion Roussel, Ltd.
Tokyo 107-8465 (JP)(72) Inventors:
• SHIMURA, Takesada
Hoechst Marion Russel Ltd.
Kawagoe-shi, Saitama 350-11 (JP)• Toriyama, Satsuki
Hoechst Marion Russel Ltd.
Kawagoe-shi, Saitama 350-11 (JP)(74) Representative:
Vieillefosse, Jean-Claude et al
Hoechst Marion Roussel
Département des Brevets
102, Route de Noisy
93235 Romainville Cedex (FR)**(54) CARTILAGE/BONE INDUCING MATERIALS FOR REPARATION**

(57) A cartilage and bone morphogenetic repairing material which contains a bone morphogenetic protein and a polyoxyethylene-p-oxypropylene glycol. In particular, it is preferable that a molecular weight of a polypropylene glycol, i.e., a component of said polyoxyethylene-polyoxypropylene glycol, being in the range of about 1,500-4,000 and a weight ratio of ethylene oxide being in the range of 40-80%/molecule, and a concentration of said polyoxyethylene-polyoxypropylene glycol in an aqueous solution being about 10-50%.

It may be applied in a cartilage and bone morphogenetic method requiring no surgical operation and which comprises a bone morphogenetic protein and a carrier having a high bio-absorption, a good affinity to the bone morphogenetic protein and capable of temperature dependent gel-sol reversible transition. It is convenient to apply locally to the site of bone fracture or

bone defect with efficient treatment effect.




FIG. 1

EP 0 884 052 A1

Description

Field of the Invention

5 The present invention relates to a cartilage and bone morphogenetic repairing material for the treatment of bone fracture and bone defect. In more detail, this invention is concerned with the cartilage and bone morphogenetic repairing material which contains a polyoxyethylene-polyoxypropylene glycol and a bone morphogenetic protein.

Background of the Invention

10 For repairing cartilages and bones, in addition to auto-plasty, there has been practiced a procedure in which a prosthetic material for defected sites of cartilage and bone composed of a combination of a bone morphogenetic protein and a suitable carrier was imbedded in the defected site. In practicing this, the defected site can be exposed on surgical operation to apply a cartilage and bone repairing material containing a bone morphogenetic protein directly to the
15 defected site, and thus the materials in a solid form such as blocks, sponges, sheets and the like which are easy to handle have been widely applied. Those in a semisolid form such as gels or pastes can also be used. As the carriers which make such solid or semisolid forms applicable, there have been utilized, for example, metals such as stainless or titanium alloys or collagen and hydroxyapatite (HAP) or a mixture thereof.

On the other hand, an attempt has been made to administer a bone morphogenetic protein for the treatment of
20 bone fracture or osteoarthritis without requiring any surgical operation. This administration mode has been earnestly desired from a viewpoint that non-invasive administration, namely injection mode, would alleviate pains from patients. However, the injection route of a simple aqueous liquid preparation of a bone morphogenetic protein causes diffusion and disappearance of the drug after administration, and so in order to achieve an effective administration, the bone morphogenetic protein should be retained in the injected site over a certain period of time. In view of the above, there has
25 been envisaged a carrier which may be in a liquid state capable of passing through a needle on administration and then phasetransited to a gel-like state after administration to retain the bone morphogenetic protein in the injected site. Preferably, the carrier may have non-toxicity, a good bio-compatibility and a high bio-absorption in a living body.

Collagen is a known carrier for a bone morphogenetic protein and is confirmed to possess favorable bio-compatibility and bio-absorption (Japanese Patent Publication No. 75425/1993). Collagen with an injectable character has also
30 been reported, which may provide an injectable cartilage and bone morphogenetic material (Japanese Patent Publication Nos. 23322/1995 and 53140/1993). However, collagen now available for the use of medicines is derived from natural sources such as cattle or a pig, so that its properties such as a molecular weight, an amino acid composition and a moisture holding property are not always constant. In addition, it has some side-effects such as antigenicity because it is a heterologous protein to human. In particular, antigenicity cannot be completely eliminated even when atelocollagen; i.e., collagen from which teropeptide sites are removed, is used (J. American Academy of Dermatology 10, 638-
35 646 and 647-651, 1984 and *ibid.* 21, 1203-1208, 1989). On the other hand, it was reported that biodegradable polymers such as polylactic acid or polylactic acid-glycolic acid copolymers can be used as pharmaceutical carriers (U.S. Patent No. 5,385,887 and Japanese Patent Publication No. 22570/1994). However, the biodegradable polymers are in a solid or semisolid state which may maintain a given form, and in view of this, they are classified as a group of applicable
40 materials to surgical operation. Even if an injectable complex can be prepared using such biodegradable polymers, an organic solvent should be employed during the preparation process, which may easily anticipate the problem of inactivation of the active ingredient, a bone morphogenetic protein.

Detailed Description of the Invention

45 It is an object of this invention to provide a cartilage and bone morphogenetic repairing material, which can overcome the prior art disadvantages or drawbacks as discussed above, which have a high bio-absorption and a good affinity to the active ingredient or a bone morphogenetic protein, and which show the sustained disposition of a bone morphogenetic protein by causing a temperature dependent sol-gel reversible transition with less side-effects such as
50 antigenicity and so on.

The present inventors have made earnest studies on the relationship between the active ingredient, a bone morphogenetic protein, and a carrier therefor in the case of a bone repairing method without surgical operation and have found that a certain class of polyoxyethylene-polyoxypropylene glycols can show a high bio-absorption, a good affinity to a bone morphogenetic protein and temperature dependent sol-gel reversible transition. The present inventors have
55 prepared a bone morphogenetic material by mixing an aqueous polyoxyethylene-polyoxypropylene glycol solution and a bone morphogenetic protein, which is an injectable liquid at a temperature of from 1°C to 30°C at the time of administration and may be gelatinized at around 37°C within 3 minutes after administration. They have found that ectopic cartilage and bone morphogenesis are accomplished by administering said material to mice intramuscularly at the femoral

muscle and then retaining a bone morphogenetic protein at the administration sites *in vivo*, upon which this invention has been completed.

This invention is concerned with a cartilage and bone morphogenetic repairing material which contains a polyoxyethylene-polyoxypropylene glycol and a bone morphogenetic protein.

The polyoxyethylene-polyoxypropylene glycol(s) as used herein is a generic name of nonionic surface active agents of a polymer type having less hydrophilic polypropylene glycols as a hydrophobic group and ethylene oxide as a hydrophilic group. It may be feasible to prepare surface active agents having various properties by changing a molecular weight of the polypropylene glycol and a mixing ratio thereof to the ethylene oxide. The synthesizable polyoxyethylene-polyoxypropylene glycols have a molecular weight of the polypropylene glycol in the range of 900-4,000 and a percent by weight of the ethylene oxide in the total molecule of 5%-90%. For instance, the polyoxyethylene-polyoxypropylene glycol block polymers (ADEKA®) manufactured by Asahi Denka Kogyo K.K. are systematically named according to a molecular weight of polypropylene glycol and a weight ratio of the ethylene oxide to be added and the classification list thereof is shown in Fig. 1.

Industrial utilization of polyoxyethylene-polyoxypropylene glycols includes aperients, ointment bases, artificial blood, coating for tablets, excipients, solubilizers or solubilizing agents for injections and others in the field of pharmaceuticals, in addition to the use as general cleaning agents or antifoamings. In particular, Pluronic F-68 (a molecular weight of polypropylene glycol of 1,750 and an ethylene oxide content of 80%) has a remarkable antihemolytic action and has been marketed in the name of EXOCOPOL® from the Green Cross Corporation as an additive for extracorporeal circulation of blood. It is apparent from the results of toxicity tests using various animals that polyoxyethylene-polyoxypropylene glycols have extremely low toxicity and low irritative property, with no reports on possible side-effects such as antigenicity and so on (Fragrance Journal, 7, 82-87, 1974). The results of toxicity tests are shown in Table 1.

Table 1

Results of acute toxicity tests using ADEKA® Pluronics		
ADEKA® Pluronics	Animal species	LD ₅₀ (g/kg)
L-44, L-62, L-64	Rats	5
F-68	Mice	>15
F-68	Rats, Rabbits, Dogs	No acute toxicity
P-85	Rats	34.6

Polyoxyethylene-polyoxypropylene glycols are superior in terms of handiness to collagen showing non-reversible phase-transition by changes in temperatures in the point that they show reversible sol-gel phase-transition. This property may be controlled by selection of the optimum polyoxyethylene-polyoxypropylene glycol for the temperature to develop the phase-transition and by changing the concentration of an aqueous solution of said polyoxyethylene-polyoxypropylene glycol (Int. J. Pharm. 22, 207-218, 1984 and EP 0551626A1).

It is obvious from the foregoing that polyoxyethylene-polyoxypropylene glycols have a superior nature as a drug carrier. Attempts have already been made to combine them with a low molecular weight drug such as local anesthetics, anticancer agents and so on (Int. J. Pharm. 8, 89-99, 1981 and Chem. Pharm. Bull. 32, 4205-4208, 1984) and to admix with a high molecular weight physiologically active protein such as interleukins and the like (Pharm. Res. 9, 425-434, 1992).

This invention relates to a cartilage and bone morphogenetic repairing material which contains a polyoxyethylene-polyoxypropylene glycol and a bone morphogenetic protein, wherein the polypropylene glycol as a constituent of said polyoxyethylene-polyoxypropylene glycol has a molecular weight of about 1,500-4,000 and an ethylene oxide content of about 40-80%/molecule. Within the above ranges, there will be provided the Pluronics capable of performing temperature-dependent sol-gel reversible transition, which characterized the present Pluronics.

Moreover, this invention relates to a cartilage and bone morphogenetic repairing material wherein a concentration of polyoxyethylene-polyoxypropylene glycols as described above in an aqueous solution is about 10-50%. It is known that the reversible phase transition temperature of polyoxyethylene-polyoxypropylene glycols varies in general depending on the concentration of their prepared aqueous solutions, and the polyoxyethylene-polyoxypropylene glycols within the above-mentioned constituent ranges may gelate at around body temperature, i.e., about 37°C at a concentration of about 10-90% in its aqueous solution. As the most preferable example, there is prepared the polyoxyethylene-polyoxypropylene glycol block polymer aqueous solution of 15-30% concentration having a molecular weight of polypropylene glycol of 3,850 and a ethylene oxide content of 70% (Pluronic F-127).

The bone morphogenetic protein (BMP) as used herein is the protein having an activity to induce undifferentiated

mesenchymal cells to cartilage cells, thereby performing bone morphogenesis.

The bone morphogenetic proteins used in this invention include, but are not limited to, a series of proteins belonging to the TGF- β gene superfamily such as BMP-2 to BMP-9 and so on, the protein named MP52, the protein named GDF-5 and the like. Particularly preferable BMP-2 is a protein produced using Chinese hamster ovary (CHO) cells according to the genetic engineering technology reported by Wang, et al. (Proc. Natl. Acad. Sci. USA, 87, 2220-2224, 1990 and U.S. Patent No. 4,877,864), and particularly preferable MP52 is a new protein produced according to the genetic engineering technology suggested by the present inventors (our copending Japanese Patent Application No. 93644/1995). This new protein can be produced by constructing a plasmid containing the DNA sequence coding the amino acid sequence as shown in SEQ ID No.:1 of the Sequence Listing derived from MP52 and having added the codon coding methionine at the N-terminal of said DNA sequence; transforming the plasmid into *E. coli*; incubating the *E. coli* to obtain an inclusion body; and solubilizing and purifying the inclusion body to obtain a monomer protein, which is then dimerized and purified.

An aqueous solution of 15-30% polyoxyethylene-polyoxypropylene glycol block polymer containing as an active ingredient BMP-2 or MP52 was intramuscularly injected to mice at the femoral muscle. MP52 was retained at the administered sites and then an ectopic cartilage and bone morphogenesis ability was observed *in vivo*.

There has not yet been reported to date an injectable cartilage and bone morphogenetic repairing material comprising a polyoxyethylene-polyoxypropylene glycol in combination with a bone morphogenetic protein which may be useful for repair of cartilage and bone, especially as a treating agent for bone fracture.

The present invention is further concerned with a cartilage and bone repairing agent containing a polyoxyethylene-polyoxypropylene glycol and a bone morphogenetic protein.

Moreover, the present invention is concerned with a method of treatment for a cartilage and bone repairing, by which a cartilage and bone morphogenetic agent comprising a polyoxyethylene-polyoxypropylene glycol in combination with a bone morphogenetic protein is administered locally to the site of bone fracture or bone defect of human or animal.

Brief Explanation of Drawings

Fig. 1 is a classification figure for ADEKA® Pluronic, wherein an ethylene oxide content in terms of % by weight in a total molecule of a polyoxyethylene-polyoxypropylene glycol is indicated on the abscissa, while a molecular weight of the component polypropylene glycol in a polyoxyethylene-polyoxypropylene glycol is indicated on the ordinate.

Fig. 2 is soft X-ray photographs of the bone/cartilage calcified tissues of the femur in the right hind leg of the mouse as obtained by Example 4. The photographs (a) and (b) were taken after 2 weeks from the administration of ADEKA® Pluronic F-127 solely and ADEKA® Pluronic F-127 containing MP52, respectively. The apparently blackened parts in the muscle indicate ectopically formed bones.

Fig. 3 is microscopic photographs of the stained tissues of the non-decalcified sections of the femur of the right hind leg of the mouse as obtained by Example 4. Formations of bone matrices and bone matrices together with osteoblasts and of bone marrows can be confirmed by von-Kossa staining (a) and Hematoxylin-Eosin staining (b), respectively.

Fig. 4 is a plasmid map of the expression vector of the protein MP52 (pKOT245) as obtained by Reference Example 1 (2).

Description of the Preferred Embodiments

The effects of this invention will be illustratively explained by way of the following Examples and Reference Examples. However, this invention is not to be restricted by these Examples.

Example 1 Preparation of cartilage and bone morphogenetic repairing material containing BMP-2

ADEKA® Pluronic F-127 (Asahi Denka Kogyo K.K.) is known to be one of the least toxic polyoxyethylene-polyoxypropylene glycols ("SEIYAKU KOJO" 6, 875-880, 1986). In 7.0 g of distilled water for injection was dissolved under ice-cooling 3.0 g of ADEKA® Pluronic F-127 to prepare a 30% aqueous solution of ADEKA® Pluronic F-127. The aqueous solution of ADEKA® Pluronic F-127 was poured portionwise under ice-cooling to a 96-well titer plate at 360 μ l/well, 40 μ l of 0.01 N HCl containing 80 μ g of BMP-2 was added to each well and mixed. The mixture was sterilized by passing through a 0.22 μ m filter at 4°C to form a BMP-2 injection of a total volume of about 400 μ l (a final concentration of ADEKA® Pluronic F-127 of 27%). Similarly, the BMP-2 injections having final concentrations of ADEKA® Pluronic F-127 of 10, 15, 18 and 22.5% were prepared.

It was found that injection was feasible at 5°C or lower in the case of the final concentration of ADEKA® Pluronic F-127 of 27%, at 10°C or lower in the case of the final concentration of ADEKA® Pluronic F-127 of 22.5%, or at 25°C or lower in the case of the final concentration of ADEKA® Pluronic F-127 of 10%-18%, while the ADEKA® Pluronic F-127 injection phase-transited to a gel-like state at 37°C was a preparation having a final concentration of 15% or higher.

Accordingly, the most preferable is a preparation of ADEKA® Pluronic F-127 with the final concentration of 18%, which was in a liquid state at room temperature and showed a gelatinized state at 37°C.

Example 2 Preparation of cartilage and bone morphogenetic repairing material containing MP52

The MP52 injections having final concentrations of ADEKA® Pluronic F-127 of 10, 15, 18, 22.5 and 27% were prepared according to the same procedure as described in Example 1. The same injectable preparations as described for the case of the BMP-2 was obtained according to MP52; that is to say, the injectable preparations applicable at 5°C or lower in the case of the final concentration of ADEKA® Pluronic F-127 of 27%, at 10°C or lower in the case of the final concentration of ADEKA® Pluronic F-127 of 22.5%, or at 25°C or lower in the case of the final concentration of ADEKA® Pluronic F-127 of 10%-18%.

Example 3 Residual rates of MP52 *in vivo* after administration of cartilage and bone morphogenetic repairing material

The ¹²⁵I-labeled MP52 injections having the final concentrations of ADEKA® Pluronic F-127 of 18, 22.5 and 27%, which had been prepared following the same method and formulation as Example 2 except that ¹²⁵I-labeled MP52 was further added, were intramuscularly administered to male mice (ICR strain, 8 weeks old) under anesthesia at the femur of the right hind leg at 100 µl using a 23G needle (about 37KBq ¹²⁵I-MP52/site) and then the radioactivity in the right hind leg was counted at 0.5, 2 and 8 hours after administration. The injection of an ¹²⁵I-MP52 aqueous solution was used as a control. The results are shown in Table 2.

Table 2

¹²⁵ I-MP52 residual rates at the right hind leg after administration of ADEKA® Pluronic F-127 preparations (ADEKA® Pluronic F-127 final concentration of 18%) or aqueous liquid preparation		
Time (hr)	Pluronic preparation	Aqueous liquid preparation
0.5	60.5%	32.7%
2	19.7%	13.8%
8	14.9%	7.9%

It was clearly shown in Table 2 that MP52 when a polyoxyethylene-polyoxypropylene glycols were used as a pharmaceutical carrier could apparently be retained more as compared with the case where a simple MP52 aqueous solution was injected. Also, similar results were obtained using the injection of Example 1.

Example 4 Pharmacological effect on ectopic cartilage and bone morphogenesis

The MP52 injection of ADEKA® Pluronic F-127 final concentration of 18% as prepared in Example 2 was intramuscularly administered to male mice (ICR strain, 8 weeks old) under anesthesia at the femur of the right hind leg at 100 µl using a 23G needle (20 µg MP52/site). The ADEKA® Pluronic F-127 injection containing no MP52 was used as a control. Cartilage and bone formation was determined after two weeks from the administration. The mice were sacrificed by vertebral cervical dislocation and the right hind leg of the administration site was cut off and bone formation at the administration site was examined by using a soft X-ray irradiator. The results are shown in Fig. 2 (n=5). As apparent from the soft X-ray images, no shadow was observed in the muscles at the administration site in the case of ADEKA® Pluronic F-127 only (Fig. 2-a), while clear shadow was observed in 80% or more of the animals with ADEKA® Pluronic F-127 containing MP52 (Fig. 2-b).

And then, after taking images using soft X-ray, the specimens were kept in 10% formalin and histologic examination was carried out. The microscopic photograph of the stained tissue of the mouse seen at the right end in Fig. 2-b is shown in Fig. 3. In Fig. 3, deposition of calcium was observed at the shadowed portion by von-Kossa staining (Fig. 3-a) and osteoblasts, bone matrices and bone marrows were confirmed by Hematoxylin-Eosin staining (Fig. 3-b), whereby bone formation was confirmed. No inflammatory reaction was observed. In these figures, bone matrix, osteoblast and bone marrow are abbreviated as BM, OB and MA, respectively.

Similar test was carried out using the BMP-2 injection having a 18% final concentration of ADEKA® Pluronic F-127 to give similar results.

From the aforesaid results, safety and usefulness of a polyoxyethylene-polyoxypropylene glycol were confirmed when used as a carrier for the bone forming factor.

Referential Example Production of new protein MP52

1. Construction of vector

(1) Isolation of variant MP52 mature part

Human MP52cDNA was amplified by polymerization chain reaction (PCR) of the mature part only, using the plasmid vector containing cDNA described in WO93/16099 (pSK52s) as a template DNA.

A part of the DNA of the mature type MP52 gene was substituted according to the method for increasing in the productivity of the desired protein by increasing the AT content around the initiation codon ATG (reported by M. Nobuhara et al., Agric. Biol. Chem., 52 (6), 1331-1338, 1988).

Substitution was carried out according to the PCR method using an orthodromic PCR primer of SEQ ID NO.:2. The DNA sequence of the PCR primer utilized the DNA described in SEQ ID NO.:2 as an orthodromic primer and that described in SEQ ID NO.:3 as an antidromic primer.

PCR was carried out by adding in the same test tube the template DNA (10 ng), 50 picomoles each of the orthodromic and antidromic PCR primers, dNTP (0.2 mmol) and $MgCl_2$ (1.5 mmol), together with Taq DNA polymerase (5 U).

The PCR of 30 cycles was performed, each cycle comprising denaturation (94°C, one minute), primer annealing (55°C, one minute) and primer elongation (72°C, 2 minutes) (All the following PCRs were performed under the above-defined conditions.).

The product from the PCR method was separated by electrophoresis in 1.5% low-melting agarose (available from FMC) to cut out the DNA composed of about 360 bp corresponding to the amino acid sequence of SEQ ID NO.:1, which is defined as Fragment 1.

(2) Construction of *E. coli* expression vector for the present protein

In order to increase the replication number of plasmid, the replication origin was altered from pBR cell line to pUC cell line. The tac promoter region of commercially available *E. coli* expression vector pKK223-3 (purchased from Pharmacia Biotech AB) was digested by the restriction enzymes SspI and EcoRI, treated with Mung Bean Nuclease (Takara Shuzo K.K., Catalogue No. 2420A), ligated to the initiation codon site of Fragment 1 with T4DNA Ligase (Takara Shuzo K.K., Catalogue No. 2011A), and the *rrnBT₁T₂* terminator region of pKK223-3 was digested with the restriction enzymes Sall and SspI, ligated to the termination codon site of Fragment 1 digested with Sall, integrated into the SmaI site of pUC18 to construct the expression vector for the production of the present protein [pKOT245 (Fig. 4)] which was deposited (Accession Number BIKOKENKI FERM-P 14895) at the National Institute of Bioscience and Human-Technology (NIBH), Agency of Industrial Science and Technology located in 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan on April 14, 1995, and transferred to a deposit (Accession No. BIKOKEN-KI FERM BP-5499) on April 10, 1996 according to Budapest Treaty on the International Recognition of the Deposit of Microorganisms. The DNA of pKOT245 has a length of 3.7 kb. The expression vector for the present protein as constructed was determined for its base sequence by means of Pharmacia ALF DNA sequencer.

(3) Transformation

Transformation was performed according to the rubidium chloride method by Kushner et al. (Genetic Engineering, p. 17, Elsevier (1978)). That is to say, pKOT245 was migrated into a host *E. coli* W3110M according to the above-mentioned procedure to prepare the *E. coli* capable of producing the present protein.

2. Cultivation

(1) Cultivation

The present protein producing *E. coli* was precultured in modified SOC medium (Bacto tryptone 20 g/l, Bacto yeast extract 5 g/l, NaCl 0.5 g/l, $MgCl_2 \cdot 6H_2O$ 2.03 g/l, Glucose 3.6 g/l) and 100 ml of the mycelium suspension was added to 5 L of the productive medium (Bacto tryptone 5 g/l, Citric acid 4.3 g/l, K_2HPO_4 4.675 g/l, KH_2PO_4 1.275 g/l, NaCl 0.865 g/l, $FeSO_4 \cdot 7H_2O$ 100 mg/l, $CuSO_4 \cdot 5H_2O$ 1 mg/l, $MnSO_4 \cdot nH_2O$ 0.5 mg/l, $CaCl_2 \cdot 2H_2O$ 2 mg/l, $Na_2B_4O_7 \cdot 10H_2O$ 0.225 mg/l, $(NH_4)_6Mo_7O_{24} \cdot 4H_2O$ 0.1 mg/l, $ZnSO_4 \cdot 7H_2O$ 2.25 mg/l, $CoCl_2 \cdot 6H_2O$ 6 mg/l, $MgSO_4 \cdot 7H_2O$ 2.2 g/l, Thiamine HCl 5.0 mg/l, Glucose 3 g/l) and then cultured with stirring and aeration in a 10 L cul-

ture tank and isopropyl- β -D-thiogalactopyranoside was added at a concentration of 1 mM at the stage of a logarithmic growth phase ($OD_{550}=5.0$) and then cultivation was continued until the OD_{550} reached 150. During the cultivation, the temperature was controlled to 32°C and a pH value was adjusted to 7.15 by adding ammonia, while a dissolved oxygen concentration was controlled to 50% of air saturation by increasing a stirring speed to prevent any reduction in the dissolved oxygen concentration. On the other hand, cultivation was carried out by adding a 50% glucose solution at 0.2% concentrations using as a standard a rapid increase in the dissolved oxygen concentration in order to keep a high mycelium concentration.

(2) Preparation of *E. coli* inclusion body

The cultured broth obtained as above was centrifuged to recover the mycelium, which was then suspended in 25 mM Tris-HCl buffer containing 10 mM ethylenediaminetetraacetic acid (pH 7.3) and then bacteria were broken by means of a mycelium breaking apparatus (available from Gohlin Co., Inc.) and centrifuged again to recover the precipitate containing the inclusion body.

3. Purification

(1) Solubilization of *E. coli* inclusion body

The *E. coli* inclusion body was washed thrice with 1% Triton X-100 and then centrifuged at 3,000 X g at 4°C for 30 minutes. The precipitate thus obtained was solubilized under ultrasonification with 20 mM Tris-HCl buffer, pH 8.3, 8 M urea, 10 mM DTT and 1 mM EDTA.

(2) Purification of monomer

The solubilized liquid thus obtained was centrifuged at 20,000 X g at 4°C for 30 minutes to recover the supernatant. The resultant supernatant was passed through SP-Sepharose FF (Pharmacia) which had been equilibrated with 20 mM Tris-HCl buffer (pH 8.3), 6 M urea, and 1 mM EDTA, washed with said solution and then eluted with said solution containing 0.5 M sodium chloride. To the eluate were added Na_2SO_3 and $Na_2S_4O_6$ at the respective final concentrations of 111 mM and 13 mM and sulfonation was carried out at 4°C for 15 hours. The sulfonated solution was gel-filtrated with Sephacryl S-200 (Pharmacia) which had been equilibrated with 20 mM Tris-HCl buffer (pH 8.3), 6 M urea, 0.2 M sodium chloride and 1 mM EDTA to obtain a single sulfonated protein monomer of the invention.

(3) Refolding

To a solution of the sulfonated protein monomer of the invention was added a 9 times volume of 50 mM Na-Glycine buffer (pH 9.8), 0.2 M sodium chloride, 16 mM CHAPS, 5 mM EDTA and 2 mM GSH (glutathione of reduced type) and 1 mM GSSG (glutathione of oxidized type), and then the mixture was stirred at 4°C for one day to perform refolding.

(4) Purification of dimer

The sample was diluted into a two-times volume of purified water and then added by 6 N NaCl adjusting pH to approximately pH 7.4 and placed to isoelectric precipitation. The precipitation collected by centrifugation at 3,000 x g for 20 minutes was solubilized in a solution with 30% acetonitrile containing 0.1% TFA. The solution was diluted in to a two-times volume of purified water and loaded on RESOURCE RPC column (Pharmacia) of a reverse-phase HPLC which had been equilibrated with 25% acetonitrile containing 0.05% TFA, and then eluted with a linear gradient of 25-45% acetonitrile containing 0.05% TFA. The eluate was monitored at 280 nm absorbance. The purified homodimer protein fractions were collected and lyophilized by Speedback Concentrator (Servant Co.).

(5) Determination of physico-chemical properties of the preset purified protein

(a) Analysis of N-terminal amino acid sequence

The present purified protein obtained as above was analyzed for the N-terminal amino acid sequence by mean of an amino acid sequencer, Model 476A (Applied Biosystems) to confirm the amino acid sequence from the N-terminal up to the 30th amino acid as shown in SEQ ID NO.:1 of the Sequence Listing.

(b) Analysis of amino acid composition

The present purified protein obtained as above was investigated by means of an amino acid analyzer [PICO TAG System (Waters Co., Ltd.)]. The results are shown in Table 3 wherein the numerical indication means the number of the amino acid residue per monomer.

Table 3

Amino acid	Practical No.	Estimated No.
Asx	11.5	12
Glx	10.9	11
Ser	8.4	9
Gly	4.3	4
His	4.0	4
Arg	7.7	7
Thr	5.4	6
Ala	7.3	7
Pro	10.2	10
Tyr	2.9	3
Val	5.7	7
Met	5.1	4
1/2Cys	2.6	7
Ile	4.9	6
Leu	10.0	10
Phe	4.0	4
Lys	5.9	6
Trp	-	2
Sequenece length		119
-: undetectable		

(c) Analysis by electrophoresis

The molecular weight of the present purified protein obtained above was confirmed by means of SDS-PAGE under non-reductive conditions to show a molecular weight of about 28KDa.

It has been proved from the results shown in the aforesaid items (a), (b) and (c) that the present protein is a protein consisting of 119 amino acid residues simply starting from the N-terminal of Pro.

Industrial Utilization The cartilage and bone morphogenetic repairing material ac

cording to the invention can be applied to the affected site in the bone fracture therapy requiring no surgical operation in a simple and painless manner due to a high bio-absorption, a favorable affinity to the active ingredient, i.e., a bone morphogenetic protein, and a temperature dependent sol-gel reversible transition. Thus, the drug effect of a bone morphogenetic protein may be sustained and further a cartilage and bone morphogenetic repairing material with less side-effects may be provided.

[Sequence Listing]

SEQ ID NO.:1

SEQUENCE LENGTH:119

SEQUENCE TYPE:amino acid

TOPOLOGY:linear

MOLECULE TYPE:peptide

FRAGMENT TYPE:N-terminal fragment

ORIGINAL SOURCE:

ORGANISM:homo sapiens

PROPERTIES:human embryo

SEQUENCE FEATURE :

LOCATION:

OTHER INFORMATION:amino acid sequence from 383 to 501 in MP52

amino acid sequence

SEQUENCE DESCRIPTION:

CCA	CTG	GCC	ACT	CGC	CAG	GGC	AAG	CGA	CCC	AGC	AAG	AAC	CTT	AAG	GCT	48
Pro	Leu	Ala	Thr	Arg	Gln	Gly	Lys	Arg	Pro	Ser	Lys	Asn	Leu	Lys	Ala	
				5					10					15		

CGC	TGC	AGT	CGG	AAG	GCA	CTG	CAT	GTC	AAC	TTC	AAG	GAC	ATG	GGC	TGG	96
Arg	Cys	Ser	Arg	Lys	Ala	Leu	His	Val	Asn	Phe	Lys	Asp	Met	Gly	Trp	
			20					25					30			

GAC	GAC	TGG	ATC	ATC	GCA	CCC	CTT	GAG	TAC	GAG	GCT	TTC	CAC	TGC	GAG	144
Asp	Asp	Trp	Ile	Ile	Ala	Pro	Leu	Glu	Tyr	Glu	Ala	Phe	His	Cys	Glu	
		35					40					45				

GGG	CTG	TGC	GAG	TTC	CCA	TTG	CGC	TCC	CAC	CTG	GAG	CCC	ACG	AAT	CAT	192
Gly	Leu	Cys	Glu	Phe	Pro	Leu	Arg	Ser	His	Leu	Glu	Pro	Thr	Asn	His	
	50					55					60					

GCA	GTC	ATC	CAG	ACC	CTG	ATG	AAC	TCC	ATG	GAC	CCC	GAG	TCC	ACA	CCA	240
Ala	Val	Ile	Gln	Thr	Leu	Met	Asn	Ser	Met	Asp	Pro	Glu	Ser	Thr	Pro	
	65				70					75					80	

CCC	ACC	TGC	TGT	GTG	CCC	ACG	CGA	CTG	AGT	CCC	ATC	AGC	ATC	CTC	TTC	288
Pro	Thr	Cys	Cys	Val	Pro	Thr	Arg	Leu	Ser	Pro	Ile	Ser	Ile	Leu	Phe	
			85					90						95		

ATT	GAC	TCT	GCC	AAC	AAC	GTG	GTG	TAT	AAG	CAG	TAT	GAG	GAC	ATG	GTC	336
Ile	Asp	Ser	Ala	Asn	Asn	Val	Val	Tyr	Lys	Gln	Tyr	Glu	Asp	Met	Val	
			100					105					110			

GTG	GAG	TCG	TGT	GGC	TGC	AGG										357
Val	Glu	Ser	Cys	Gly	Cys	Arg										
			115													

SEQ ID NO.:2

SEQUENCE LENGTH:27

SEQUENCE TYPE:nucleic acid

STRANDNESS:single

TOPOLOGY:linear

MOLECULE TYPE:other nucleic acid

ORIGINAL SOURCE:none

ORGANISM:none

CELL LINE:none

SEQUENCE FEATURE: orthodromic PCR primer for isolation of
mature type MP52

SEQUENCE DESCRIPTION:

ATAATGCCAC TAGCAACTCG TCAGGGC 27

SEQ ID NO.:3

SEQUENCE LENGTH:26

SEQUENCE TYPE:nucleic acid

STRANDNESS:single

TOPOLOGY:linear

MOLECULE TYPE:other nucleic acid

ORIGINAL SOURCE:none

ORGANISM:none

CELL LINE:none

SEQUENCE FEATURE: antidromic PCR primer for isolation of
mature type of MP52

SEQUENCE DESCRIPTION:

CGTCGACTAC CTGCAGCCAC ACGACT 26

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Hoechst Marion Roussel Ltd.
- (B) STREET: 17-51, Akasaka 2-chome, Minato-ku
- (C) CITY: TOKYO
- (E) COUNTRY: JAPAN
- (F) POSTAL CODE (ZIP): 107-8465
- (G) TELEPHONE: 81.355.71.64.02
- (H) TELEFAX: 81.355.71.62.13

(ii) TITLE OF INVENTION: CARTILAGE/BONE INDUCING MATERIALS FOR REPARATION

(iii) NUMBER OF SEQUENCES: 3

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) and Word 97

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: EP 96938460.1

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: JP 7-322402
- (B) FILING DATE: 17-NOV-1995

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 357 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..357
- (D) OTHER INFORMATION: /note= "Relevant amino acid residues in SEQ ID No 1 from 1 to 119 in WO 95/04819"

(x) PUBLICATION INFORMATION:

- (A) AUTHORS: HOTTEN, Gertrud
NEIDHARDT, Helge
PAULISTA, Michael
- (B) TITLE: New growth/differentiation factor of the tgfbeta familie
- (C) JOURNAL: Patent : WO 95/04819
- (G) DATE: 16-02-1995

EP 0 884 052 A1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

5	CCA CTG GCC ACT CGC CAG GGC AAG CGA CCC AGC AAG AAC CTT AAG GCT	48
	Pro Leu Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala	
	1 5 10 15	
	CGC TGC AGT CGG AAG GCA CTG CAT GTC AAC TTC AAG GAC ATG GGC TGG	96
	Arg Cys Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp	
	20 25 30	
10	GAC GAC TGG ATC ATC GCA CCC CTT GAG TAC GAG GCT TTC CAC TGC GAG	144
	Asp Asp Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu	
	35 40 45	
15	GGG CTG TGC GAG TTC CCA TTG CGC TCC CAC CTG GAG CCC ACG AAT CAT	192
	Gly Leu Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His	
	50 55 60	
	GCA GTC ATC CAG ACC CTG ATG AAC TCC ATG GAC CCC GAG TCC ACA CCA	240
	Ala Val Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro	
	65 70 75 80	
20	CCC ACC TGC TGT GTG CCC ACG CGA CTG AGT CCC ATC AGC ATC CTC TTC	288
	Pro Thr Cys Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe	
	85 90 95	
25	ATT GAC TCT GCC AAC AAC GTG GTG TAT AAG CAG TAT GAG GAC ATG GTC	336
	Ile Asp Ser Ala Asn Asn Val Val Lys Gln Tyr Glu Asp Met Val	
	100 105 110	
	GTG GAG TCG TGT GGC TGC AGG	357
	Val Glu Ser Cys Gly Cys Arg	
	115	
30		

(2) INFORMATION FOR SEQ ID NO: 2:

35	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 27 base pairs
	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: single
	(D) TOPOLOGY: linear
40	(ii) MOLECULE TYPE: other nucleic acid
	(A) DESCRIPTION: /desc = "OLIGONUCLEOTIDE"
	(ix) FEATURE:
	(A) NAME/KEY: misc_feature
	(B) LOCATION: 1..27
45	(D) OTHER INFORMATION: /note= "PCR forward primer for isolating mature-type MP52"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

50	ATAATGCCAC TAGCAACTCG TCAGGGC	27
----	-------------------------------	----

(2) INFORMATION FOR SEQ ID NO: 3:

55

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "OLIGONUCLEOTIDE"

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
 (B) LOCATION: complement (1..26)
 (D) OTHER INFORMATION: /note= "PCR reverse primer for
 isolating mature-type MP52"


(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CGTCGACTAC CTGCAGCCAC ACGACT

26

Claims

1. A cartilage and bone morphogenetic repairing material which comprises a polyoxyethylene-polyoxypropylene glycol and a bone morphogenetic protein.
2. The cartilage and bone morphogenetic repairing material as claimed in claim 1, wherein the polypropylene glycol as a constituent of said polyoxyethylene-polyoxypropylene glycol has a molecular weight of about 1,500-4,000 and an ethylene oxide content of about 40-80%/molecule.
3. The cartilage and bone morphogenetic repairing material as claimed in claim 2, wherein a concentration of said polyoxyethylene-polyoxypropylene glycol in an aqueous solution is about 10-50%.
4. The cartilage and bone morphogenetic repairing material as claimed in either one of claims 1-3, wherein said bone morphogenetic protein is BMP-2.
5. The cartilage and bone morphogenetic repairing material as claimed in either one of claims 1-3, wherein said bone morphogenetic protein is MP52.
6. A cartilage and bone repairing agent comprising a polyoxyethylene-polyoxypropylene glycol and a bone morphogenetic protein.
7. A method of treatment for a cartilage and bone repairing, whereby a cartilage and bone morphogenetic agent comprising a polyoxyethylene-polyoxypropylene glycol in combination with a bone morphogenetic protein is administered locally to the site of bone fracture or bone defect of human or animal.



F I G. 1

(a)



(b)



Fig. 2





Fig. 3



F I G . 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP96/03333

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl ⁶ A61K38/18, A61K47/32, A61F2/28, A61B17/56, A61M37/00 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. Cl ⁶ A61K38/18, A61K47/32, A61F2/28, A61B17/56, A61M37/00 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE, WPI/L on DERWENT		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P	WO, 96/21427, A (Atrix Laboratories, Inc.), July 18, 1996 (18. 07. 96) & AU, 9646525, A	1, 6
Y	WO, 94/1483, A (Collagen Corp.), January 20, 1994 (20. 01. 94), Page 10, lines 13 to 14; page 15, line 4 & JP, 8-502082, A & US, 5292802, A & EP, 648239, A	1-4, 6
Y	JP, 61-277612, A (Kiyoshi Morikawa), December 8, 1986 (08. 12. 86) (Family: none)	1-4, 6
Y	JP, 6-508777, A (Genetics Institute, Inc.), October 6, 1994 (06. 10. 94) & WO, 93/50, A & EP, 591392, A	1-4, 6
Y	JP, 62-135431, A (Koken K.K.), June 18, 1987 (18. 06. 87) (Family: none)	1-4, 6
Y	JP, 1-265968, A (Collagen Corp.),	1-4, 6
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search January 20, 1997 (20. 01. 97)		Date of mailing of the international search report January 28, 1997 (28. 01. 97)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP96/03333

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	October 24, 1989 (24. 10. 89) & US, 4863732, A & EP, 321277, A & DE, 3869577, A	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No. —

PCT/JP96/03333

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 7 pertains to methods for treatment of the human or animal body by therapy and thus relates to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)